{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458284525
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = o
| target = GD3 [[ganglioside]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 216503-58-1
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| IUPHAR_ligand = 7981
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05061
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}

'''Mitumomab''' ('''BEC-2''') is a [[mouse]] anti-BEC-2 [[monoclonal antibody]] investigated for the treatment of [[small cell lung carcinoma]] in combination with [[Bacillus Calmette-Guérin|BCG]] vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the [[immune system]]. It was developed by [[ImClone]] and [[Merck Serono|Merck]].<ref>{{cite web|url=http://adisinsight.springer.com/drugs/800003245 |title=Mitumomab - AdisInsight |website=Adisinsight.springer.com |date=2005-06-13 |accessdate=2017-01-06}}</ref>

The first phase III [[clinical trial]] began in 1998.<ref>{{ClinicalTrialsGov|NCT00037713|Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG}}</ref><ref>{{ClinicalTrialsGov|NCT00006352|Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer}}</ref><ref>[http://webarchive.nationalarchives.gov.uk/20081211204614/http://www.pcpoh.bham.ac.uk/publichealth/horizon/outputs/documents/2003/BEC2.pdf]</ref> In 2005 and again in 2008, results were published showing no benefit to patients receiving mitumomab and BCG.<ref>{{cite journal |doi=10.1016/j.ejca.2008.06.036 |pmid=18676140 |title=Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer |journal=European Journal of Cancer |volume=44 |issue=15 |pages=2178–84 |year=2008 |last1=Bottomley |first1=Andrew |last2=Debruyne |first2=Channa |last3=Felip |first3=Enriqueta |last4=Millward |first4=Michael |last5=Thiberville |first5=Luc |last6=Addario |first6=Giannicola D' |last7=Rome |first7=Lisa |last8=Zatloukal |first8=Petr |last9=Coens |first9=Corneel |last10=Giaccone |first10=Giuseppe }}</ref><ref>{{cite journal |doi=10.1200/JCO.2005.17.186 |pmid=16192577 |title=Phase III Study of Adjuvant Vaccination with Bec2/Bacille Calmette-Guerin in Responding Patients with Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) |journal=Journal of Clinical Oncology |volume=23 |issue=28 |pages=6854–64 |year=2005 |last1=Giaccone |first1=G. |last2=Debruyne |first2=C |last3=Felip |first3=E |last4=Chapman |first4=P. B. |last5=Grant |first5=S. C. |last6=Millward |first6=M |last7=Thiberville |first7=L |last8=d'Addario |first8=G |last9=Coens |first9=C |last10=Rome |first10=L. S. |last11=Zatloukal |first11=P |last12=Masso |first12=O |last13=Legrand |first13=C }}</ref>

==See also==
*[[Anti-ganglioside antibodies]]

==References==
{{Reflist}}

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Experimental cancer drugs]]
[[Category:Abandoned drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}